Dianthus Therapeutics, Inc.
DNTH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.99 | -0.72 | -4.46 | -0.71 |
| FCF Yield | -2.05% | -3.59% | -4.26% | -3.60% |
| EV / EBITDA | -35.56 | -20.79 | -19.38 | -23.32 |
| Quality | ||||
| ROIC | -7.27% | -11.40% | -10.00% | -8.97% |
| Gross Margin | 75.00% | 48.70% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.83 | 0.76 | 0.94 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.59% | 8.57% | 32.20% | 38.48% |
| Free Cash Flow Growth | -27.66% | 13.44% | -0.65% | -29.04% |
| Safety | ||||
| Net Debt / EBITDA | 1.36 | 0.38 | 0.26 | 0.67 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,959.09 | -4,847.91 | -5,518.18 | -5,228.69 |